10-Q
Quarterly Report
10x Genomics, Inc.
TXG
NASDAQ
CIK: 1770787
File #: 001-39035
Balance Sheet
42 line items · 2 periods
XBRL
| Item | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 490,285,000 | 473,966,000 |
Marketable securities | 49,563,000 | 49,443,000 |
Accounts receivable, net | 39,031,000 | 47,013,000 |
Other receivables | 17,106,000 | 35,480,000 |
Inventory | 53,487,000 | 56,341,000 |
Prepaid expenses and other current assets | 20,261,000 | 22,208,000 |
Total current assets | 669,733,000 | 684,451,000 |
Property and equipment, net | 220,591,000 | 226,711,000 |
Operating lease right-of-use assets | 58,390,000 | 60,450,000 |
Goodwill | 4,511,000 | 4,511,000 |
Intangible assets, net | 59,910,000 | 62,329,000 |
Other noncurrent assets | 2,624,000 | 2,913,000 |
Total assets | 1,015,759,000 | 1,041,365,000 |
Liabilities and stockholders’ equity | ||
Current liabilities: | ||
Accounts payable | 17,425,000 | 12,733,000 |
Accrued compensation and related benefits | 21,506,000 | 42,500,000 |
Accrued expenses and other current liabilities | 33,680,000 | 39,971,000 |
Deferred revenue | 24,342,000 | 23,902,000 |
Products and Services, Excluding Grant Revenue - 2026-04-01 | 24,300,000 | — |
Operating lease liabilities | 11,330,000 | 10,985,000 |
Contingent consideration, current | 5,315,000 | 23,363,000 |
Total current liabilities | 113,598,000 | 153,454,000 |
Contingent consideration, noncurrent | 1,222,000 | 1,237,000 |
Operating lease liabilities, noncurrent | 70,059,000 | 73,376,000 |
Deferred revenue, noncurrent | 10,138,000 | 10,501,000 |
Other noncurrent liabilities | 6,418,000 | 6,471,000 |
Total liabilities | 201,435,000 | 245,039,000 |
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock | 2,000 | 2,000 |
Additional paid-in capital | 2,338,269,000 | 2,306,690,000 |
Accumulated deficit | (1,524,061,000) | (1,510,591,000) |
Accumulated other comprehensive income | 114,000 | 225,000 |
Total stockholders’ equity | 814,324,000 | 796,326,000 |
Common Stock | 2,000 | 2,000 |
Additional Paid-in Capital | 2,338,269,000 | 2,306,690,000 |
Accumulated Deficit | (1,524,061,000) | (1,510,591,000) |
Accumulated Other Comprehensive Income (Loss) | 114,000 | 225,000 |
Total liabilities and stockholders’ equity | 1,015,759,000 | 1,041,365,000 |